Clovis Oncology
CLVS
$0.08120
Share price
0.00%
Change (1 day)
-95.08%
Change (1 year)
Categories
Operating Margin for Clovis Oncology (CLVS)
Operating Margin as of April 2024 (TTM): -163.43%
According to Clovis Oncology's latest financial reports and stock price the company's current Operating Margin is -163.43%. At the end of 2021 the company had an Operating Margin of -178.09%.
Operating Margin history for Clovis Oncology from 2017 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -178.09% | -20.76% |
| 2020 | -224.75% | -19.37% |
| 2019 | -278.75% | -27.63% |
| 2018 | -385.16% | -38.91% |
| 2017 | -630.46% | -99.87% |
| 2016 | -488,680.77% | |
| 2014 | -1,157.60% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.88% | -114.00% | 🇺🇸 USA |
 Pfizer PFE | 34.61% | -121.18% | 🇺🇸 USA |
 AbbVie ABBV | 18.65% | -111.41% | 🇺🇸 USA |
 Eli Lilly LLY | 24.66% | -115.09% | 🇺🇸 USA |
 AstraZeneca AZN | 5.63% | -103.44% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | 4.83% | -102.96% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.